Treatment | Study name | Data cutoffa (MM/DD/YYYY) | Median study follow-up, months (range) | Analysis set | N |
---|---|---|---|---|---|
Efficacy outcomes | |||||
 Liso-cel | TRANSCEND [6] | 08/12/2019 | 11.5 (0.2‒35.0)b | DLBCL efficacy set | 256 |
 Tisagenlecleucel—ORR, CR rate | JULIET [8] | 12/08/2017 | 14 (0.1‒26)c | Efficacy analysis set | 93 |
 Tisagenlecleucel—PFS, OS | JULIET [8] | 12/08/2017 | 14 (0.1‒26)b | Safety set/full analysis set | 111 |
Safety outcomes | |||||
 Liso-cel | TRANSCEND [6] | 08/12/2019 | 11.5 (0.2‒35.0)b | DLBCL-treated set | 269 |
 Tisagenlecleucel | JULIET [8] | 12/08/2017 | 14 (0.1‒26)c | Safety set/full analysis set | 111 |